Insider Buying: DiaMedica Therapeutics (NASDAQ:DMAC) Major Shareholder Purchases $1,732,937.92 in Stock

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) major shareholder Jan Stahlberg purchased 240,352 shares of DiaMedica Therapeutics stock in a transaction that occurred on Wednesday, November 19th. The stock was purchased at an average price of $7.21 per share, with a total value of $1,732,937.92. Following the transaction, the insider owned 8,375,092 shares in the company, valued at $60,384,413.32. This represents a 2.95% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Jan Stahlberg also recently made the following trade(s):

• On Tuesday, November 25th, Jan Stahlberg acquired 73,099 shares of DiaMedica Therapeutics stock. The shares were purchased at an average price of $8.57 per share, for a total transaction of $626,458.43.
• On Monday, November 24th, Jan Stahlberg bought 40,253 shares of DiaMedica Therapeutics stock. The shares were purchased at an average cost of $7.89 per share, for a total transaction of $317,596.17.
• On Friday, November 21st, Jan Stahlberg bought 208,872 shares of DiaMedica Therapeutics stock. The stock was acquired at an average cost of $7.41 per share, with a total value of $1,547,741.52.
• On Thursday, November 20th, Jan Stahlberg purchased 128,426 shares of DiaMedica Therapeutics stock. The shares were acquired at an average price of $7.41 per share, for a total transaction of $951,636.66.
• On Tuesday, November 18th, Jan Stahlberg purchased 182,882 shares of DiaMedica Therapeutics stock. The shares were acquired at an average cost of $6.75 per share, for a total transaction of $1,234,453.50.
• On Monday, November 17th, Jan Stahlberg acquired 187,393 shares of DiaMedica Therapeutics stock. The stock was acquired at an average cost of $6.52 per share, with a total value of $1,221,802.36.

DiaMedica Therapeutics Price Performance

NASDAQ:DMAC opened at $9.35 on Thursday. The stock has a market cap of $486.95 million, a PE ratio of -13.17 and a beta of 1.31. DiaMedica Therapeutics, Inc. has a fifty-two week low of $3.19 and a fifty-two week high of $10.42. The stock’s 50-day moving average is $7.24 and its two-hundred day moving average is $5.79.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). On average, equities research analysts anticipate that DiaMedica Therapeutics, Inc. will post -0.59 earnings per share for the current year.

Institutional Trading of DiaMedica Therapeutics

Several large investors have recently made changes to their positions in DMAC. Cooperman Leon G raised its stake in shares of DiaMedica Therapeutics by 98.2% in the 3rd quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after acquiring an additional 1,619,761 shares in the last quarter. Millennium Management LLC bought a new stake in DiaMedica Therapeutics during the third quarter worth approximately $8,157,000. Paragon Associates & Paragon Associates II Joint Venture grew its holdings in DiaMedica Therapeutics by 34.6% during the third quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after purchasing an additional 225,000 shares during the last quarter. Geode Capital Management LLC raised its position in shares of DiaMedica Therapeutics by 99.6% in the second quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock valued at $2,458,000 after purchasing an additional 314,407 shares during the period. Finally, Royal Bank of Canada raised its position in shares of DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after purchasing an additional 154,701 shares during the period. Institutional investors own 10.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Wall Street Zen lowered shares of DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Wednesday, October 8th. TD Cowen began coverage on DiaMedica Therapeutics in a research note on Thursday, October 30th. They set a “buy” rating for the company. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of DiaMedica Therapeutics in a research note on Friday, August 15th. Finally, Cowen initiated coverage on DiaMedica Therapeutics in a report on Thursday, October 30th. They issued a “buy” rating on the stock. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $12.33.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.